Integrated Discovery
One Scientific Partner. From Hit Discovery to IND.
Managing multiple CROs can slow your drug discovery programme through fragmented data, inconsistent methodologies, and delayed decision-making. ImmunitasBio provides an integrated drug discovery platform that delivers a seamless, regulatory-ready path from Hit Identification to IND-enabling studies for mAbs, ADCs, CAR-T, CAR-NK, cell & gene therapies, and small molecules.
Why Choose ImmunitasBio?
Instead of coordinating multiple vendors, partner with one scientific team that ensures:
- End-to-end drug discovery support
- Consistent assay platforms and methodologies
- Integrated, regulatory-ready data packages
- Faster project execution and reduced timelines
- One quality system from discovery through IND
Our Drug Discovery Workflow
Target Identification
Validate therapeutic targets through immunology research, expression profiling, and functional biology studies in relevant cellular models.
Hit Identification
Identify promising candidates using advanced cell-based screening, binding assays, and phenotypic screening tailored to your therapeutic modality.
Lead Optimization
Optimize lead candidates through potency, selectivity, mechanism of action (MOA), ADCC/CDC, and functional characterization studies.
Candidate Selection
Compare shortlisted candidates using efficacy, safety, mechanistic, and functional assays to support confident development candidate selection.
IND-Enabling Studies
Generate regulatory-grade efficacy, pharmacokinetic (PK), toxicology, and quality testing data required for successful IND submissions.
Therapeutic Modalities We Support
Monoclonal Antibodies (mAbs)
Comprehensive antibody characterization including binding, MOA, Fc effector functions, ADCC, CDC, and safety profiling.
Antibody-Drug Conjugates (ADCs)
Complete ADC biology services including target engagement, internalization, payload activity, bystander killing, and functional efficacy studies.
Cell & Gene Therapies
Specialized assays for CAR-T, CAR-NK, and other cell therapies, including potency, cytotoxicity, cytokine profiling, co-culture models, and exhaustion marker analysis.
Small Molecules
Target-based and phenotypic screening, immune cell assays, selectivity profiling, and mechanism of action studies for small-molecule drug discovery.
